Replimune

Q1 FY2027 EarningsQ1 FY27 results showed a GAAP EPS of -$0.72, slightly missing the consensus of -$0.699, while revenue remained at zero as expected for this pre-commercial stage. The operating loss of -$68.2M was largely in line with the -$67.9M consensus, reflecting disciplined R&D and SG&A spending which decreased significantly YoY. The defining milestone was the August 6 FDA accelerated approval of TUDRIQEV, with a commercial launch planned within 60 days supported by a recent $150M financing that extends the cash runway for over 12 months.